2-Hydrazino-β-(indol-3-yl)-propionsaeure | 6765-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Hydrazino-β-(indol-3-yl)-propionsaeure
• 英文别名: 3--2-hydrazino-propionsaeure；2-Hydrazino-3-(indol-3-yl)-propionsaeure；2-hydrazino-3-indol-3-yl-propionic acid；2-Hydrazino-3-(1H-indol-3-yl)-propionic acid；2-hydrazinyl-3-(1H-indol-3-yl)propanoic acid
• CAS: 6765-43-1
• 化学式: C₁₁H₁₃N₃O₂
• 分子量: 219.243
• InChiKey: YJLGBPOTRWZBFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  91.1
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation
  申请人：Trustees of Boston College

  公开号：US20180360984A1

  公开（公告）日：2018-12-20

  Novel biomolecular conjugates containing non-natural aromatic chemical moieties covalently coupled to a diazonium compound and methods of their use are disclosed.

  揭示了含有非天然芳香化学基团的新型生物分子共轭物，其与重氮化合物共价耦合，并公开了它们的使用方法。
• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• DIPEPTIDE LINKED MEDICINAL AGENTS
  申请人：Indiana University Research and Technology Corporation

  公开号：US20160158375A1

  公开（公告）日：2016-06-09

  A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration.

  提供了一种非酶自裂二肽元素，可通过酰胺键与已知药物剂量连接。在生理条件下，由于化学不稳定性驱动的反应，二肽将自发地从药物剂量中裂解。因此，二肽元素提供了一种将各种化合物链接到已知药物剂量的手段，其中化合物在暴露于生理条件一定时间后随后从药物剂量中释放出来。例如，二肽可以与药物的活性位点连接以形成前药，或二肽可以包含一个沉淀聚合物，以将包含复合物的注射剂量隔离在给药点处。
• Sustained-release preparation of anti-endothelin substance
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0647449A1

  公开（公告）日：1995-04-12

  A sustained-release preparation containing an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.

  一种含有抗内皮素物质和生物可降解聚合物的缓释制剂。 本发明的缓释制剂能持续释放抗内皮素物质，可用于治疗内皮素相关疾病。
• Sustained-release preparation
  申请人：——

  公开号：US20020058622A1

  公开（公告）日：2002-05-16

  According to a first embodiment, there is provided a sustained-release preparation comprising a water-insoluble or slightly water-soluble polyvalent metal salt of a water-soluble physiologically active substance which is not an endothelin antagonist, and a biodegradable polymer. The sustained-release preparation of the first embodiment is highly efficient in incorporating the water-soluble physiologically active substance and suppresses the initial burst of the water-soluble physiologically active substance. The sustained-release preparation of the present invention is capable of releasing the water-soluble physiologically active substance while retaining its bioactivity after administration in vivo. Furthermore, the water-soluble physiologically active substance in the sustained-release preparation is kept stable for a long period of time, with little loss of bioactivity. According to a second embodiment, there is provided a sustained-release preparation comprising an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.

  根据第一个实施方案，提供了一种缓释制剂，该制剂包含一种不溶于水或微溶于水的水溶性生理活性物质的多价金属盐，该生理活性物质不是内皮素拮抗剂，还包含一种可生物降解的聚合物。第一实施方案中的缓释制剂能高效地掺入水溶性生理活性物质，并抑制水溶性生理活性物质的初始迸发。本发明的缓释制剂能够释放水溶性生理活性物质，同时在体内给药后保持其生物活性。此外，本发明的缓释制剂中的水溶性生理活性物质可保持长期稳定，生物活性损失小。 根据第二个实施方案，本发明提供了一种由抗内皮素物质和生物可降解聚合物组成的缓释制剂。本发明的缓释制剂可持续释放抗内皮素物质，在治疗内皮素相关疾病中发挥良好作用。